About The Study:

Major Depressive Disorder (MDD), commonly known as clinical depression, is a pervasive mental health condition characterized by persistent and profound feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Individuals grappling with MDD often experience disruptions in sleep patterns, appetite, and energy levels. The impact extends beyond emotional distress, affecting cognitive functions such as concentration and decision-making. MDD can manifest as a single episode or recur throughout a person’s life, significantly impairing their ability to function in social, occupational, and personal spheres.

The purpose of this research study is to evaluate the safety of solriamfetol (oral product) in subjects with Major Depressive Disorder. This is a phase 3 study and, in this trial, there is a 50% chance of placebo. If previous attempts at managing your MDD have been unsuccessful, this study could be a suitable option for you. There is no cost to participate in this research study and health insurance is not required nor needed.

*Please note, this study is for participants where their major depressive disorder is the prevalent problem. 

Qualifications

  • Must be between the ages of 18 to ≤65 years old
  • Must have a BMI 18 to ≤40 kg/m2
  • Must have a diagnosis of Major Depressive Disorder
  • Must be in a current depressive episode
  • Cannot be on any ADHD medications
  • *Please note, other qualifications apply